Sigvotatug Vedotin Phase 3 Trial for NSCLC Reaches Primary Completion

By Hipa.ai Research · March 12, 2026

Synced daily from openFDA and ClinicalTrials.gov. Last sync: June 12, 2026.

On March 12, 2026, the Phase 3 clinical trial (NCT06012435) investigating sigvotatug vedotin for previously treated non-small cell lung cancer (NSCLC) reached its primary completion. This study is evaluating sigvotatug vedotin against docetaxel in this patient population.

Background

Sigvotatug vedotin is an experimental antibody drug being studied for the treatment of nonsquamous non-small cell lung cancer (NSCLC). This condition involves cancer that has spread throughout the body or cannot be surgically removed. Patients enrolled in the trial had received prior treatment, specifically no more than a platinum-based chemotherapy and an anti-PD-(L)1 drug. For those with tumors harboring certain treatable genomic alterations, at least one drug targeting that alteration was also required, in addition to platinum-based chemotherapy.

Trial design

The study, titled "A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer" (NCT06012435), is a Phase 3 clinical trial. It enrolled 703 participants diagnosed with Carcinoma, Non-Small-Cell Lung. The trial design involves comparing the experimental drug sigvotatug vedotin against docetaxel. The primary completion indicates that all participants have completed their final visits or data collection for the primary endpoint, though specific outcome measurements are not yet available.

What this means

The primary completion of this Phase 3 trial for sigvotatug vedotin signifies a key milestone in its development for previously treated non-small cell lung cancer. While specific results are not yet released, reaching primary completion means that the collection of data for the trial's main objectives is complete. The anticipated results will provide crucial information on the efficacy and safety profile of sigvotatug vedotin compared to docetaxel, potentially offering a new therapeutic option for patients with advanced NSCLC who have exhausted other treatments.

Source

Information regarding the primary completion of this trial was sourced from ClinicalTrials.gov, a public database of clinical studies. The update for study NCT06012435, titled "A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer," was recorded on 2026-03-12 on clinicaltrials.gov.